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. Through this mechanism, cellular homeostasis is maintained during periods of feeding and starvation. Drugs and other xenobiotics can also differentially modulate PPAR-regulatory activities.
Whether PPARs function as tumour suppressors or as oncogenes in cancer is still unclear. The complexity of the pathways that are regulated by PPARs, and the propensity of these pathways to be altered in cancer, offers some explanation for the disparate functions of PPARs in different tumour types. However, as targeting PPARs can improve the clinical consequences of metabolic disorders that are known to be associated with increased cancer risk (such as diabetes, obesity, dyslipidemias and chronic inflammation), modulating the activities of the PPARs is an attractive approach for the treatment and prevention of cancer. The challenge is to elucidate the molecular mechanisms of action of PPAR agonists in different tissues and tumour types, and to identify and characterize effective PPAR agonists that have acceptable safety profiles. The progress in understanding PPAR function and translating this to the clinic is discussed below. In this Review, we pay particular attention to the controversial function of PPARβ/δ in colorectal cancer.
PPAR-mediated gene expression
Substantial progress has been made in delineating the molecular mechanisms that mediate PPAR-regulated gene expression and associated cellular functions (FIG. 1) . Following ligand binding, PPARs undergo a conformational change that causes the release of histone deacetylase (HDAC) co-repressors, thus enabling PPARs to heterodimerize with retinoid X receptor (RXR). RNA polymerase II and co-activators with histone acetyl transferase (HAT) activity are then recruited to this complex, which binds to response elements in target genes, leading to chromatin remodelling and ultimately to increased transcription (FIG. 1a) . PPARβ/δ has also been shown to repress the transcription of some target genes through binding to DNA response elements in association with co-repressors, independently of ligand binding
Agonists
Compounds that bind to a receptor that invokes a biological response that is most often transcriptionally mediated. The specificity of an agonist is often defined by its ability to bind to the receptor at a given concentration and whether it is able to interact with a single receptor.
and transcription factors through a 'trans-repression' mechanism (FIG. 1b) . For example, PPARα and PPARβ/δ can sequester the p65 subunit of the nuclear factor-κB (NF-κB) complex and can prevent NF-κB-dependent regulation of genes that are involved in pro-inflammatory responses (reviewed in . Alternatively, transrepression by PPARγ can involve its sumoylation (FIG. 1c) , through which ligand activation leads to the conjugation of PPARγ with SUMO, which binds to a nuclear co-repressor complex, causing the repression of pro-inflammatory gene expression 14 . Sumoylationdependent trans-repression might also be relevant for PPARα and PPARβ/δ because the amino acid that is sumoylated is conserved between all three PPARs 15 . Trans-repression of pro-inflammatory signalling pathways is thought to be central to the well-documented anti-inflammatory activities that are associated with PPAR ligands and PPARs 8, 15 . More recently, it has been shown that the beneficial effects of PPARγ activation in diabetics can be modulated by 'non-agonist' PPARγ ligands that inhibit the phosphorylation of PPARγ, and so are independent of the classic receptor-mediated modulation of gene transcription 16 . Thus, there are multiple levels of regulation that can be targeted to selectively alter PPAR-dependent activities.
The physiological functions of the PPARs PPARα. PPARα, which was the first PPAR to be identified 17 , is expressed in many tissues, particularly those that require fatty acid oxidation as a source of energy 18 . PPARα is central for the maintenance of lipid homeostasis: a primary role of PPARα is to increase the cellular capacity to mobilize and to catabolize fatty acids, particularly in the liver during starvation, where the oxidation of fatty acids is essential for energy production (reviewed in REF. 19) (FIG. 2) . Under these conditions, PPARα is probably activated by endogenous fatty acids and fatty acid derivatives (reviewed in REF. 19 ). PPARα is also the molecular target of fibrates, which are widely used drugs that reduce serum lipids through the increased oxidation of lipids (reviewed in REF. 19 ). The number of direct PPARα-target genes is large and has been reviewed elsewhere 20 , but it includes many that encode enzymes that are involved in glucose, lipid and amino acid metabolism 21 . PPARα can also improve insulin resistance in high-fat and genetic models of diabetes through pleiotropic changes in gene expression that prevent weight gain and adiposity 22 .
PPARβ/δ. PPARβ/δ also regulates glucose and lipid homeostasis (FIG. 2) . PPARβ/δ is expressed in most tissues in rodents and humans 18, 23 , and expression of PPARβ/δ seems to be highest in the epithelia of the intestine, colon and skin 23, 24 -in which one study has shown that it colocalizes with RXR in the nucleus 24 . Ligands that activate PPARβ/δ increase serum highdensity lipoprotein cholesterol levels in rats, non-human primates and humans [25] [26] [27] . This is probably mediated by PPARβ/δ-dependent expression of the reverse cholesterol transporter ATP-binding cassette A1 and by increased apolipoprotein A1-specific cholesterol efflux 26 . Ligand activation of PPARβ/δ can also decrease serum triglycerides, prevent high-fat diet-induced obesity, increase insulin sensitivity and improve symptoms that are associated with metabolic syndrome 26, [28] [29] [30] through the regulation of genes encoding fatty acid-metabolizing enzymes in skeletal muscle 28, 29 and genes encoding lipogenic proteins in the liver. PPARβ/δ also inhibits hepatic inflammation that is caused by genetic, dietary and chemical stimuli [31] [32] [33] [34] [35] in part by the trans-repression of NF-κB-dependent signalling, which results in reduced expression of cytokines such as tumour necrosis factor (TNF), interleukin-1β (IL-1β) and IL-6 (FIG. 1) . Activating PPARβ/δ can also promote terminal differentiation in keratinocytes, intestinal epithelium, oligodendrocytes and osteoblasts (reviewed in 36) , and this function might have important consequences for tumour development.
PPARγ. The physiological effects of PPARγ activation are primarily mediated by PPARγ1 and PPARγ2, which are derived from four different mRNAs (PPARG1, PPARG2, PPARG3 and PPARG4) 37, 38 . Comprehensive, quantitative expression patterns of PPARγ at the protein level have not yet been determined in any species, but expression of PPARγ has been demonstrated in many cell types. Significant nonspecific immunoreactivity is found
At a glance
• Peroxisome proliferator-activated receptors (PPARs) have central roles in the regulation of glucose and lipid homeostasis through their functions as molecular sensors that respond to endogenous ligands, leading to the modulation of gene expression. PPARs also regulate cell proliferation, differentiation and inflammation.
• PPARα mediates hepatocarcinogenesis induced by long-term administration of PPARα agonists in rodent models, an effect that is not found in humans. The mechanism underlying species-specific hepatocarcinogenesis is through mouse PPARα-dependent regulation of the let-7c microRNA, which leads to increased expression of the oncoprotein MYC. The current interest in targeting PPARα for the prevention of certain cancers, including colon and leukaemia, is based on studies showing that PPARα agonists inhibit the proliferation of endothelial cells, increase the synthesis of PPARγ agonists and potentially interfere with the Warburg effect.
• The role of PPARβ/δ in carcinogenesis is controversial. Several studies have shown that PPARβ/δ is upregulated in cancer cells by the adenomatous polyposis coli (APC)-β-catenin-TCF4 pathway and has a pro-tumorigenic effect in many cancer types. However, other studies have shown that PPARβ/δ agonists can induce terminal differentiation and inhibit innate inflammation, suggesting anticancer effects. In addition, a retrospective study has shown that low expression levels of PPARβ/δ are associated with the decreased survival of patients with colorectal cancer. Therefore, there remains a need to further examine PPARβ/δ protein expression patterns quantitatively in tumour models and the putative mechanisms that are mediated by PPARβ/δ agonists associated with anti-apoptotic or growth stimulatory effects.
• PPARγ agonists can induce terminal differentiation, inhibit cell proliferation, promote apoptosis and inhibit innate inflammation in many cancer models. This has led to a number of clinical trials with PPARγ agonists, but these have generated mixed results. Moreover, some PPARγ agonists have been associated with pro-tumorigenic effects. Emerging evidence indicates that targeting PPARγ in combination with other chemopreventive or chemotherapeutic agents might increase the efficacy of the effects that are induced by monotherapies.
• Owing to similarities in the abilities of the three PPARs to improve different metabolic disorders that are known to be associated with increased cancer risk (such as diabetes, obesity, dyslipidemias and chronic inflammation), modulating the activities of the PPARs remains an attractive approach for the treatment and prevention of cancer. The challenge is to advance the discovery of molecular mechanisms of action in order to identify and characterize effective PPAR agonists with acceptable safety profiles.
NCOR Nature Reviews | Cancer with some PPARγ-targeted antibodies 39, 40 , which probably affects the interpretation of results from studies examining PPARγ expression. Polyunsaturated fatty acids, fatty acid derivatives such as 15-deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2), 9-hydroxyoctadecadienoic acid (9-HODE), 13-HODE and nitrated fatty acids can activate PPARγ and may be endogenous ligands (reviewed in REF. 1). PPARγ is crucial for development, in particular of the placenta and heart 41 , and it is also essential for adipogenesis and fat storage 42, 43 (FIG. 2) . White adipose tissue is the primary target of the PPARγ agonists, the thiazolidinediones, which decrease serum lipids by increasing adipogenesis and lipid storage, and which increase the expression of various adipokines, such as adiponectin and resistin 44 , which collectively increase insulin sensitivity.
PPARs and cancer development PPARα and liver cancer. Long-term administration of PPARα agonists causes liver cancer in rodents 45 , an effect that is dependent on PPARα, as Ppara-null mice are resistant to the hepatocarcinogenic effects of PPARα agonists 46, 47 . The mode of action for the hepatocarcinogenic effect of PPARα agonists has been determined and, interestingly, this mechanism is not evident in humans (reviewed in REF. 48 ). Recent data from studies using PPARα-humanized mice (mice that express a human PPARA gene on a Ppara-null background) offer an explanation for this difference. Although the administration of PPARα agonists causes the increased expression of target genes that modulate lipid catabolism in both wild-type and PPARα-humanized mice 49 , hepatocarcinogenesis and the downregulation of the let-7c microRNA (miRNA) cluster is only evident in wild-type mice 50, 51 . The let-7c miRNA targets the mRNA that encodes MYC and, in its absence, the stability of MYC mRNA is increased, which might contribute to increased mitogenic signalling that causes hepatocyte proliferation 51 .
A controversial role of PPARβ/δ in cancer. There is no broad consensus on the role of PPARβ/δ in cancer, owing to contradictory studies in the literature (reviewed in . However, two hypotheses have emerged (FIG. 3) : that PPARβ/δ is overexpressed in tumours and promotes anti-apoptotic activities and increased cell proliferation; and that PPARβ/δ promotes terminal differentiation and inhibits pro-inflammatory signalling, thereby attenuating tumorigenesis.
An initial finding that expression of PPARB/D mRNA was higher in four colon tumours compared with nontransformed tissue was taken to indicate a role for PPARβ/δ in colon cancer progression 52 . However, in this study the expression of PPARB/D mRNA was essentially absent in non-transformed colon tissue 52 , a finding that does not agree with more recent studies from our laboratory 24, 54 and others 23, 53 in both mouse and human tissue that show that PPARβ/δ is constitutively expressed at high levels in normal colonic epithelium. The increased expression of PPARB/D mRNA in colon tumours has been attributed to APC-β-catenin-TCF4-mediated transcription, which is similar to the known β-catenin-TCF4 target gene CCND1 that encodes cyclin D1. This led to the provocative hypothesis that PPARβ/δ regulates genes that increase cell proliferation and that promote colon carcinogenesis 52 , and provided the rationale for many follow-up studies. Although some of these studies support this hypothesis, others do not (reviewed in REFS 10, 11) . One of the uncertain fundamental issues is whether PPARB/D expression is increased or decreased in tumours. Indeed, since the original report that suggested that PPARB/D expression is increased by an APC-dependent pathway, some studies have found that PPARB/D expression is higher in colon tumours than in non-transformed tissue [55] [56] [57] [58] [59] [60] [61] [62] . Studies using other tissues also indicate that the expression of PPARB/D is higher in tumour tissue than in non-transformed tissue, including ovarian carcinomas, squamous cell carcinomas, breast tumours and endometrial carcinomas [63] [64] [65] [66] [67] . By contrast, studies have also found that the expression of PPARB/D is either unchanged or lower in colorectal tumours compared with non-transformed tissue 5, 53, 54, 58, 60, [68] [69] [70] [71] [72] [73] [74] [75] [76] (reviewed in REF. 11 ), and in ovarian or bladder carcinomas compared with normal tissue 77, 78 . However, there are important limitations to most, but not all 54 , of these studies: they typically measure only mRNA expression and not protein expression; they often lack positive and negative controls; the number of samples examined is usually small; and protein expression is analysed by immunohistochemistry. The sole use of immunohistochemical analysis of PPARβ/δ is particularly problematic because any nonspecific immunoreactivity associated with PPARβ/δ-targeted antibodies could produce misleading results 79, 80 (reviewed in REF. 10 ). More extensive studies that examine whether PPARβ/δ expression is increased by the APC-β-catenin-TCF4 signalling pathway, including microarray analysis and quantitative analysis of cells or tissues with activating mutations in the β-catenin pathway, have not reported increased PPARβ/δ expression 54, 68, 72, 73, 79, 81, 82 . In addition, expression of PPARβ/δ is fairly high in normal human and mouse colon 23, 24, 53 , where it may function to maintain differentiation in response to an endogenous ligand. Although some data showing high expression of PPARβ/δ in human colon compared with other tissues are limited to an analysis of two samples from a publically available database 23 , we argue that the strength of this database lies in its ability to make comparisons of relative expression in many different human tissues. These data are consistent with recent studies showing robust expression of PPARβ/δ in human samples of untransformed colon 53, 54 and in one study in mice showing relatively high expression of PPARβ/δ in the colon and intestine compared with ten other tissue types 24 . However, it is important to note that expression of the PPARβ/δ protein does not necessarily indicate that it is active, as the protein could be modified by endogenous ligands that may or may not be present. It also remains possible that the biological outcome (promotion or inhibition of carcino genesis) of PPARβ/δ expression depends on the presence or absence of other gene products (for example, oncogenes or tumour suppressors).
A recent retrospective study in humans showed that higher expression of PPARβ/δ in primary tumours was associated with lower expression of Ki-67 (a surrogate marker of proliferation), increased frequency of stage I cases, a lower frequency of later stage cases and a lower rate of lymph node metastasis 60 . Interestingly, PPARβ/δ was differentially expressed, with some primary tumours exhibiting relatively high expression, and other primary tumours and lymph node metastases exhibiting relatively lower expression 60 . Importantly, patients with colorectal cancer with relatively low expression of PPARβ/δ were four-times more likely to die of colorectal cancer than patients with relatively higher expression of PPARβ/δ in primary tumours 60 . Given the more precise quantification of PPARβ/δ in this study, in which immunohistochemical PPARα also regulates the expression of fatty acid-catabolizing enzymes in the liver, heart and kidney. Released fatty acids are then oxidized in these tissues to ultimately generate ATP. PPARβ/δ is expressed at high levels in the intestine where it mediates the induction of terminal differentiation of epithelium (which is also important for the skin). Activating PPARβ/δ or PPARγ can increase insulin sensitivity, causing improved glucose uptake in diabetic models. PPARβ/δ regulates the expression of fatty acid-catabolizing enzymes in skeletal muscle where released fatty acids are oxidized to generate ATP. PPARγ promotes the differentiation of adipocytes. b | PPARα, PPARβ/δ and PPARγ can interfere with nuclear factor-κB (NFκB) and AP1 in tissues, including macrophages, endothelial cells, epithelial cells and others, causing the attenuation of pro-inflammatory signalling by decreasing the expression of pro-inflammatory cytokines, chemokines and cell adhesion molecules, for example, in addition to other trans-repressive mechanisms (FIG. 1) . c | The activation of PPARα and PPARβ/δ promotes osteoblast activity in bone; whereas, the activation of PPARγ promotes osteoclast activity in bone. AcCoA, acetylCoA; IL-6, interleukin-6; MCP1, monocyte chemotactic protein 1; TNF, tumour necrosis factor; TG, triglyceride. Unidentified endogenous ligands activate PPARβ/δ, increasing the expression of proteins that are required for promoting terminal differentiation and causing cell cycle withdrawal. Constitutive expression of PPARβ/δ also attenuates inflammation. Both of these effects explain how PPARβ/δ maintains cellular differentiation and homeostasis. Expression of PPARβ/δ in tumour cells is decreased through undefined mechanisms. This causes the deregulation of terminal differentiation and inflammatory signalling that collectively causes increased cell proliferation and reduced apoptosis, resulting in tumour promotion. In this model, ligand activation of PPARβ/δ prevents tumorigenesis and is most consistent with recent findings. The strengths of this model include that low expression of PPARβ/δ has been quantified in some tumour types and that higher expression levels have been shown in normal cells and tissues. This is consistent both with data showing that PPARβ/δ is involved in cell differentiation and with some PPARβ/δ ligands possessing the ability to inhibit cell proliferation. In addition, the activation of PPARβ/δ is anti-inflammatory and this might partly explain why ligand-activated PPARβ/δ decreases tumorigenesis in some studies, as does the pan-PPAR agonist bezafibrate. This model is also consistent with a recent retrospective study showing the reduced survival of patients with colorectal cancer who exhibited relatively low expression of PPARβ/δ in their primary tumours. The weaknesses of this model include that the expression of PPARβ/δ is variable in tumour types and normal tissues, and that several studies have shown that ligand activation of PPARβ/δ increases cell proliferation and tumorigenesis. b | A model based on the reduced expression of PPARβ/δ in normal cells is shown. Unidentified endogenous ligands activate PPARβ/δ, increasing the expression of unidentified target genes that promote cell cycle progression and inhibit apoptosis. The expression of PPARβ/δ in tumour cells is increased through undefined mechanisms or by direct upregulation that is mediated by APC-β-catenin-dependent signalling found in several tumour types. Unidentified endogenous ligands activate PPARβ/δ, modulating the expression of PTEN, integrin linked kinase (ILK) and 3-phosphinositoldependent protein kinase 1 (PDPK1) or vascular endothelial growth factor (VEGF), which collectively increase the phosphorylation (P) of AKT, causing inhibition of apoptosis. Alternatively, unidentified target genes that increase cell cycle progression could also be important. This model could explain how non-steroidal anti-inflammatory drugs (NSAIDs) inhibit tumorigenesis, although the reduced expression of PPARβ/δ is inconsistent both with the anti-inflammatory role of PPARβ/δ and with data from other studies showing that NSAIDs increase PPARβ/δ levels and induce apoptosis. The strengths of this model include that increased expression of PPARβ/δ is found in some tumour types, which is consistent with studies that show that ligand activation of PPARβ/δ induces tumour development. In addition, this model might explain how cyclooxygenase (COX)-derived metabolites promote cancer. The weaknesses of this model include that other studies have shown that PTEN, PDPK1, VEGF and AKT are not affected by PPARβ/δ, PPARβ/δ expression is not upregulated by β-catenin and TCF4, PPARβ/δ does not promote anti-apoptotic activities, and ligand activation of PPARβ/δ decreases cell proliferation and tumorigenesis. This model is also inconsistent with studies showing relatively high constitutive expression of PPARβ/δ in epithelia. ADRP, adipose differentiation related protein; FABP, fatty acid binding protein.
analysis was supported by western blot analyses, a large number of patients (141) and many years of follow-up (~15 years), this is currently the best evidence to support the hypothesis that PPARβ/δ has a protective role in human colorectal cancer. Interestingly, a recent study has shown that the survival of patients with colorectal cancer whose tumour samples stained positive for both PPARβ/δ and cyclooxygenase 2 (COX2) expression was reduced compared with patients with tumours that stained positive for only PPARβ/δ or COX2, or that were not immunoreactive for either of these proteins 62 . This suggests that increased expression of PPARβ/δ in the presence of relatively high COX2 expression could cooperatively promote colorectal cancer. However, it is important to note that this study relies on immunohistochemistry only for estimating PPARβ/δ protein expression; there is no comparison of patient survival for those with lower versus higher expression of PPARβ/δ alone (the differences in PPARβ/δ expression between tumour samples is not described); and there is no comparison of survival for patients with different-stage disease whose tumours were positive for COX2 only, as patients exhibiting this phenotype with early stage I tumours should survive longer than those exhibiting this phenotype with stage II-IV tumours 83 . Much like the conflicting human data, elucidating the function of PPARβ/δ in mouse cancer models has been confounded by conflicting results (reviewed in REFS 9-12). For example, some studies indicate that colon carcinogenesis is exacerbated in the absence of PPARβ/δ expression and/or that ligand activation of PPARβ/δ attenuates tumorigenesis 5, 70, 74, 84 . Other studies have found that colon carcinogenesis is inhibited in the absence of PPARβ/δ expression, and that ligand activation of PPARβ/δ promotes tumorigenesis [85] [86] [87] . Similar paradigms exist for other tumour types (reviewed in REFS 9-12), although not all. For example, there is good evidence that PPARβ/δ protects against, and that ligand activation of PPARβ/δ attenuates, chemically induced skin carcinogenesis [88] [89] [90] [91] [92] . Some studies show that activating PPARβ/δ increases proliferation and/or inhibits apoptosis in a variety of human lung, breast, liver and prostate cancer cell lines, and in some cases correlative studies in animal models support these findings (reviewed in REFS 9, 10) . However, studies from other laboratories show that activating PPARβ/δ either inhibits or has no effect on proliferation, and has no effect or promotes apoptosis, in human lung, breast and liver cancer cell lines; correlative studies in animal models also support some of these in vitro studies (reviewed in REFS 9, 10) . Thus, more work is needed in mouse models to try and understand the complexities of PPARβ/δ expression in tumorigenesis. One possible factor that might influence the role of PPARβ/δ in cancer development or suppression is its effect on angiogenesis
. However, the function of PPARβ/δ and PPARγ in angiogenesis is also controversial.
Several mechanisms have been proposed to explain the pro-carcinogenic effect of PPARβ/δ. Three of these mechanisms are partly based on data from cells that resemble normal mouse primary keratinocytes 93, 94 . Analyses of these cells suggested that ligand activation of PPARβ/δ increases the expression of 3-phosphoinositide-dependent-protein kinase 1 (PDPK1) and integrin linked kinase (ILK), and decreases the expression of PTEN, causing increased phosphorylation of AKT, leading to anti-apoptotic signalling and enhanced cell survival 93 (FIG. 3) . Since this initial report, some studies in cancer models have supported these findings, but others have not (reviewed in . Issues of contention include whether true keratinocytes were studied in the models that were used to suggest this pathway was functional 93, 94 . Our studies have shown that in human N/TERT-1 and HaCaT keratinocytes, and in mouse primary keratinocytes that express keratin 6 and normal patterns of keratinocyte differentiation markers, PTEN is not decreased, expression of PDPK1 and ILK is not increased and/or phosphorylation of AKT is not increased by ligand activation of PPARβ/δ, despite clear upregulation of known PPARβ/δ-target genes 95, 96 . Indeed, we have also found that ligand activation of PPARβ/δ inhibits the proliferation of mouse keratinocytes, mouse neoplastic keratinocytes, human HaCaT keratinocytes and N/TERT-1 human keratinocytes, and does not promote survival 88, 89, [95] [96] [97] . Microarray analyses also show that the expression of PDPK1, ILK and PTEN mRNA is unaffected by ligand activation of PPARβ/δ [98] [99] [100] [101] . In our studies, ligand activation of PPARβ/δ does not promote the survival of human cancer cell lines or HaCaT keratinocytes following the induction of apoptosis by a variety of stimuli 4, 54, 95, 102 . Thus, we think that there are inherent limitations in establishing ILK-PDPK1-PTEN-AKT pro-survival signalling as a mechanism that is mediated by PPARβ/δ.
A related mechanism that has been proposed to explain the pro-carcinogenic effects of PPARβ/δ is also based on the idea that PPARβ/δ promotes cell survival by regulation of ILK-PDPK1-PTEN-AKT. It was suggested that the high ratio of intracellular fatty acid binding protein 5 to cellular retinoic acid binding protein II found in these cells diverts all-trans retinoic acid to PPARβ/δ rather than to the retinoic acid receptor that is thought to cause increased expression of PDPK1, leading to anti-apoptotic activities and increased cell survival 103 . However, follow-up studies do not concur with these findings 4 (reviewed in REF. 9 ). Another related mechanism is based on the analysis of human colon cancer cell lines and Apc min/+ mice. Ligand activation of PPARβ/δ increases the expression of vascular endothelial growth factor (VEGF) through a PPARβ/δ-dependent mechanism, causing increased phosphorylation of AKT, which promotes cell survival by blocking apoptosis 86 . Several studies have also found evidence supporting this mechanism, primarily by showing increased expression of VEGF in colon tumours or in colon cancer cell lines following treatment with a PPARβ/δ ligand 87, 104, 105 . However, we have not found altered expression of either VEGF or phosphorylation of AKT in similar models in response to activation of PPARβ/δ 102 . It has also been shown that PPARβ/δ confers resistance to PPARγ-induced apoptosis in some cancer cells on the basis of the expression levels of both proteins in HCT116 and LS174T cells 59 . However, we and others have shown that the ratio of PPARβ/δ/PPARγ is low in HCT116 cells; that expression of PPARβ/δ is actually similar between HCT116 and LS174T cells; and that expression of PPARγ is much lower in HCT116 cells than in LS174T cells 39, 52, 79 . This suggests that the observed resistance to PPARγ-induced apoptosis in HCT116 cells could reflect differences in expression of PPARγ rather than differences in expression of PPARβ/δ.
Two mechanisms have been proposed to explain the chemopreventive effects of PPARβ/δ (FIG. 3) . The hypothesis that PPARβ/δ promotes the induction of terminal differentiation is supported by evidence from multiple models, including keratinocytes, intestinal epithelium, osteoblasts, oligodendrocytes and monocytes, as well as in a variety of cancer models, including colon, breast and neuroblastoma cells (reviewed in 36) . This mechanism involves the increased expression of gene products that are required for terminal differentiation, the altered expression of gene products that inhibit cell proliferation and the inhibition of cell proliferation -effects that are not seen in cells that lack expression of PPARβ/δ (reviewed in 36) . Abundant evidence also supports the idea that PPARβ/δ can inhibit pro-inflammatory signalling. For example, more than 50 studies show that PPARβ/δ can inhibit the expression of pro-inflammatory signalling by decreasing the expression of TNF, IL-1β, IL-6 and monocyte chemotactic protein 1 (MCP1; also known as CCL2) (reviewed in . Many of these changes in the expression of pro-inflammatory signalling proteins are thought to be mediated by the direct inhibition of NF-κB-dependent signalling (reviewed in REFS 8-13) (FIG. 1) , but PPARβ/δ-dependent inhibition of AP1 and signal transducer and activator of transcription 3 (STAT3) phosphorylation has also been described (reviewed in REFS 8-13). As inflammation is associated with the development of many cancers 106 , and antiinflammatory drugs are known to effectively prevent some cancers, it is curious that no studies have yet specifically examined whether activating PPARβ/δ could prevent tumorigenesis by inhibiting inflammation. Given the strength of evidence that PPARβ/δ can mediate potent anti-inflammatory activities, this hypothesis warrants detailed examination.
PPARγ and cancer.
The function of PPARγ in tumour development is also controversial. There are many published studies showing that activating PPARγ prevents cancer in tissues such as colon, breast, prostate and lung (reviewed in REFS 107, 108) . Indeed, most studies to date show that PPARγ agonists can promote terminal differentiation, inhibit cell growth and increase apoptosis of human cancer cell lines, as well as inhibit tumorigenesis in animal models of cancer; in some cases, PPARγ agonists have also shown modest efficacy for chemoprevention in clinical trials (reviewed in REFS 107, 108) . Overall survival of patients with colorectal cancer is markedly better when PPARγ expression is detectable in primary tumours than in patients with colorectal cancer who have no detectable PPARγ expression in their primary tumours 109 , which is a similar result to that from the retrospective study that examined a relationship between the survival of patients with colorectal cancer and expression of PPARβ/δ 60 . This is consistent with results showing that colon tumorigenesis is exacerbated in APC min/+ mice with genetic ablation of Pparg compared with control APC min/+ mice 110 . Ligand activation of PPARγ in cancer cell lines is associated with the induction of cell cycle arrest, the increased expression of mRNAs and proteins required for terminal differentiation, including keratins, carcinoembryonic antigen, E-cadherin, alkaline phosphatase and developmentally-regulated GTP-binding protein 1 (DRG1), as well as with the changes to cell morphology that are consistent with a differentiated phenotype [111] [112] [113] [114] [115] . One mechanism that may mediate PPARγ-dependent induction of terminal differentiation is through an interaction with HIC5 (also known as TGFB1I1), which may be a PPARγ co-activator 116 . In this model, HIC5 and PPARγ cooperatively increase the expression of fatty acid-binding protein, kruppel-like factor 4 (KLF4) and keratin 20; proteins that are known to be required for epithelial differentiation 116 . Through this mechanism, cells differentiate and so undergo obligate cell cycle arrest (FIG. 4) .
PPARγ agonists modulate the expression of different cell cycle regulators, including decreasing the expression of cyclin D1 , increasing the expression of the cyclin-dependent kinase inhibitors p21 (REFS 111, 122) and p27 and increasing the turnover of β-catenin 128, 129 . PPARγ agonists can also inhibit cell proliferation by inactivating eukaryotic initiation factor 2, which leads to the inhibition of translation initiation 130 . Although it is known that these changes contribute to the mechanisms through which PPARγ agonists inhibit cell cycle progression, the precise involvement of PPARγ in causing these changes remains uncertain.
Box 1 | Controversial role of PPARs in angiogenesis
The role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) and PPARγ in angiogenesis remains uncertain. Angiogenesis is a complex process that provides a blood supply to growing tumours and involves the production of growth factors, such as vascular endothelial growth factor (VEGF), to stimulate proliferation of endothelial cells, release of proteases and expression of cell adhesion molecules to allow proliferating endothelial cells to form new blood vessels. Studies show that PPARβ/δ ligands can either increase or decrease VEGF expression in cancer cells and endothelial cells 221, 222 , and increase or decrease proliferation of endothelial cells: endothelial cells from Pparb/d-null mice proliferate faster than those from wild-type mice (reviewed in REF. 10 ). Functional studies revealed that activating PPARβ/δ promotes angiogenesis in both in vitro and in vivo models [223] [224] [225] , and could explain some of the pro-tumorigenic effects that are associated with PPARβ/δ expression. Although the mechanism remains uncertain, PPARβ/δ may regulate angiogenesis by inhibiting the proliferation of endothelial cells 224 . PPARγ can either promote or inhibit angiogenesis in both in vitro and in vivo models depending on the context [226] [227] [228] [229] [230] . PPARγ agonists can also increase expression of VEGF in cancer cells 221, 231 , but decrease endothelial cell viability 227 . The anti-angiogenic effects of PPARγ activation might be mediated by downregulation of the VEGF receptor, whereas the pro-angiogenic effects might be due to increased endothelial nitric oxide synthase activity. Because PPARβ/δ and PPARγ cause differential effects on regulatory pathways that modulate angiogenesis (such as VEGF expression and endothelial cell proliferation), and there can be differences in the outcome of functional analyses, there is currently no consensus for the role of these receptors in angiogenesis and whether they are involved in enhancing or inhibiting metastasis. Nature Reviews | Cancer Increased apoptotic signalling is another mechanism that mediates the growth inhibitory effects of PPARγ agonists. PPARγ agonists can increase the expression of pro-apoptotic BAX and BAD 131, 132 , inhibit BCL-X L and BCL-2 function 131, 133 , increase the expression of PTEN [134] [135] [136] [137] [138] , inhibit PI3K activity and AKT phosphorylation 134, 139, 140 , inhibit activation of JUN N-terminal protein kinase 131 and increase turnover of the antiapoptotic protein FLICE inhibitory protein (FLIP) 141, 142 . Many of these changes increase caspase activity and apoptosis. Although there is some evidence that PPARγ may be required for regulating the expression of some of these proteins, such as PTEN 136, 137 , many changes are independent of PPARγ and probably represent offtarget effects of the individual PPARγ agonists (reviewed in REF. 143 ).
Chronic inflammation that is associated with many cancers, including colorectal, liver and lung cancer, is typically associated with increased NF-κB activity and is causally linked with tumour promotion 106 . PPARγ agonists can inhibit the production of pro-inflammatory signalling proteins, such as TNF, IL-6 and MCP1, and these changes are mediated through trans-repression mechanisms, including directly interfering with NF-κB activity and/or through receptor sumoylation (FIG. 1) . PPARγ is expressed in tumour cells and infiltrating immune cells, and there is evidence that anti-inflammatory activities are mediated by PPARγ in many cell types 15, 144 . Indeed, PPARγ expressed in intestinal epithelial cells 145 and macrophages 146 inhibits inflammation that is associated with experimentally induced colitis, and inflammation is known to be required for colon carcinogenesis 147 . Despite this evidence suggesting that activating PPARγ inhibits tumorigenesis, doubts persist because some studies indicate that activating PPARγ promotes tumorigenesis [148] [149] [150] [151] . Indeed, increased bladder cancer incidence is reported to be associated with the clinical use of rosiglitazone or pioglitazone, although there is evidence that this might reflect off-target effects of these PPARγ agonists 152, 153 . Additionally, despite a large body of in vitro and preclinical data showing that PPARγ inhibits breast cancer 154 , overexpression of a constitutively active PPARγ fusion protein caused earlier lethality compared with controls in a breast cancer model 155 . However, it is worth noting that there are substantial differences in gene expression observed between the PPARγ fusion protein and the expression typically found in response to ligand activation of PPARγ 156 . No definitive mechanisms have yet been elucidated that explain these pro-carcinogenic effects.
PPARs and cancer treatment and prevention Activation of PPARs causes physiological changes that, in theory, should make these receptors good targets for the treatment and prevention of cancer. For example, ligand activation of both PPARβ/δ and Peroxisome proliferator-activated receptor-γ (PPARγ) agonists can cause both PPARγ-dependent and PPARγ-independent alterations that inhibit tumour growth. Following ligand activation, HIC5 can act as a transcriptional co-activator of the receptor complex and can increase the expression of genes required for the induction of terminal differentiation. Ligand activation of PPARγ can also cause increased expression of caveloin, non-steroidal anti-inflammatory drug activated gene 1 (NAG1), p21 and p27 through an undefined mechanism that requires PPARγ. Ligand activation of PPARγ can attenuate inflammation by interfering with nuclear factor-κB (NF-κB) signalling and through a SUMO-dependent mechanism. In addition to these PPARγ-dependent signalling pathways, some PPARγ agonists also cause PPARγ-independent effects (off-target effects) that include induced terminal differentiation, increased apoptosis, decreased cell proliferation and inhibition of inflammation, all of which combine to inhibit tumour growth. The extent to which these changes are induced is unique for each PPARγ agonist and probably reflects differences in the functional chemical groups that are present in the PPARγ agonists. ADRP, adipose differentiation related protein; EGFR, epidermal growth factor receptor; FABP, fatty acid binding protein; FLIP, FLICE inhibitory protein; JNK, JUN N-terminal kinase; K20, keratin 20; KLF4, Kruppel-like factor 4; RXR, retinoic X receptor; Ub, ubiquitin. Nature Reviews | Cancer 
Antagonists
Compounds that bind to a receptor and that block all known receptor activities induced by activation by an agonist. The potency of an antagonist is often defined by the concentration required to inhibit activation by an agonist.
PPARγ promotes terminal differentiation (reviewed in REFS 10, 11, 36, 107, 108) . Agonists for all three PPARs are also known to exhibit potent anti-inflammatory activities 8, 15 .
PPARα. There are studies suggesting that activating PPARα could be useful for the prevention or the treatment of different cancers. Oral administration of different PPARα agonists inhibited the growth of tumours that were derived from melanoma, Lewis lung carcinoma, glioblastoma and fibrosarcoma cell lines 157 , and xenografts from A549 human lung cancer cells 158 . PPARα agonists also inhibited angiogenesis in these models 157, 158 . These inhibitory effects are mediated by the PPARα-dependent inhibition of endothelial cell proliferation, and PPARα-dependent downregulation of cytochrome P450 CYP2C, an enzyme that catalyses the epoxidation of arachidonic acid to epoxyeicosatrienoic acids 158 that promote angiogenesis. As these effects are not evident in Ppara-null mice 157, 158 , they are PPARα-dependent, and thus PPARα agonists could be used to prevent multiple tumour types (FIG. 5) .
There are two other potential PPARα-dependent pathways that could inhibit tumorigenesis or tumour growth (FIG. 5) . First, PPARα inhibits inflammatory signalling through repressive mechanisms that are mediated by interacting with the p65 subunit of NF-κB (reviewed in . Because inhibiting NF-κB-dependent signals, such as TNF, can effectively inhibit the growth of multiple tumour types 159 , targeting this PPARα-dependent activity may be useful. Second, PPARα agonists also negatively influence the Warburg effect by interfering with metabolic pathways. Ligand activation of PPARα can increase mitochondrial oxidation of fatty acids 160 , and can inhibit expression of glutaminase 21 , which decreases glutamine levels and limits cancer cell growth. As fatty acids and glutamine are enzymatically produced by the Warburg effect, and are substrates required for cell proliferation 161 , targeting PPARα to potentially inhibit tumour cell proliferation by interfering with the Warburg effect should be examined (FIG. 5) .
PPARβ/δ. The potential for developing chemical agonists or antagonists of PPARβ/δ for chemoprevention remains uncertain. Given the observations that ligand activation of PPARβ/δ can inhibit or prevent metabolic syndrome, obesity, dyslipidemias, glucose intolerance and chronic inflammation, and all of these diseases are associated with cancer development 106, 162, 163 , it is somewhat surprising that PPARβ/δ may promote carcino genesis. Despite considerable progress that has been made in the past 10 years, it is still not possible to unequivocally indicate whether an agonist would promote or attenuate most types of cancer (FIG. 3) , with the exception of non-melanoma skin cancer where the use of PPARβ/δ agonists looks promising [88] [89] [90] 92 . Several PPARβ/δ antagonists have been developed [164] [165] [166] [167] [168] , and the effect of two of these has been specifically examined in human cancer cell lines. The biologically available PPARβ/δ antagonist GSK3787 inhibits PPARβ/δ-dependent activity in vivo and in vitro, despite weak PPARγ agonist activity 169 . However, antagonism of PPARβ/δ in human cancer cell lines has no effect on cell proliferation 167, 169 . Although one study suggested that another PPARβ/δ antagonist inhibits the proliferation of the A549 human lung cancer cell line, the concentration of the antagonist that was required to cause this effect also interfered with PPARγ 168 . Given the central role of PPARβ/δ in many important biological functions (FIG. 2) , ranging from the regulation of glucose and lipid homeostasis, as well as the maintenance of terminal differentiation, to the modulation of innate inflammation and possibly cancer suppression, the development and use of a compound that specifically and exclusively antagonizes PPARβ/δ for the purpose of chemoprevention may not be feasible.
PPARγ. As studies in mouse models and cultured cells indicate that PPARγ has potential for preventing or treating cancers, clinical trials have been undertaken to determine whether PPARγ agonists can inhibit tumorigenesis and tumour progression in patients with liposarcoma, colon cancer, breast cancer or prostate cancer. Increased differentiation of liposarcoma cells was observed in patients treated with troglitazone 170 , and another clinical trial indicated that treatment with rosiglitazone increased the mean time to progression (which was defined as a doubling in tumour volume) 171 . However, no effect of rosiglitazone treatment was found in a larger cohort of patients with prostate cancer 172 . Troglitazone has been tested in patients with prostate cancer with variable results on prostate-specific antigen (PSA) levels 173, 174 , and administration of LY293111 to patients with prostate cancer had no clinical effect 175 . In two Phase II studies, troglitazone had no effect in patients with either breast cancer or colorectal cancer 176, 177 . Some clinical trials examining the effect of PPARγ ligands combined with other therapeutics revealed no effect for some studies 178, 179 , but positive results for patients with thyroid carcinoma and glioma [180] [181] [182] . It is also worth noting that a chromosomal translocation that fuses the paired box 8 gene (PAX8) with the PPARG gene is found in some cases of thyroid cancer 183 . The function of this PAX8-PPARγ fusion protein remains unclear, as some studies have shown that it acts as a dominant-negative against PPARγ activity; whereas, other studies have indicated that it retains more classic PPARγ transcriptional activity 184, 185 . Thus, the clinical trials carried out to date have yielded evidence suggesting that PPARγ might be suitable for targeting pre-cancerous and cancer cells in select tumour types.
Clinical studies show that the administration of PPARγ agonists is associated with an increased risk of heart failure 186 , bone fractures [187] [188] [189] [190] and possibly bladder cancer 153 . Whether these negative side effects are mediated by PPARγ, and whether they represent thiazolidinedione-specific or off-target effects, remains uncertain. Because PPARγ ligands can elicit different transcriptional effects owing to the differential recruitment of co-activators 191 , it is possible that unique PPARγ ligands could be developed that retain chemopreventive activities but that do not lead to negative side effects. Indeed, troglitazone was removed from the market because of idiosyncratic liver toxicity, a side effect that is not observed with rosiglitazone or pioglitazone. The screening and identification of natural compounds that retain PPARγ-dependent and/or PPARγ-independent anticancer activities could be a useful approach 143, 192 . Alternatively, the development of 'non-agonist' modulators of PPARγ that exhibit improved safety profiles might be a suitable strategy 16 . This suggests that PPARγ remains a viable target for the treatment and prevention of cancer.
Interestingly, chemicals that antagonize PPARγ can also inhibit the proliferation or invasiveness of human cancer cell lines [193] [194] [195] [196] . Studies show that some of these effects are due to PPARγ-independent mechanisms 197 , but in one study, knocking down the expression of PPARγ mitigated the anti-proliferative effect of a PPARγ antagonist in a human cancer cell line 195 . This paradoxically suggests that PPARγ antagonists might be useful for inhibiting tumorigenesis. However, there are several limitations to the suggestion that antagonizing PPARγ will inhibit tumorigenesis, including that many of the effects that are induced by current PPARγ antagonists do not require PPARγ, suggesting that other off-target mechanisms underlie these effects; the nature of the putative endogenous ligand that promotes tumorigenesis remains unclear; and chemicals that antagonize a nuclear receptor can also function as agonists, and whether this is true for the current PPARγ antagonists has not yet been extensively examined. This last point indicates that PPARγ antagonists could function similarly to tamoxifen, which retains both agonist and antagonist activities for the oestrogen receptor in a cell-and tissue-specific manner 198 . Thus, whether chemicals that target PPARγ as antagonists are useful for cancer chemoprevention remains to be determined.
Pan-and dual-PPAR agonists.
It is conceivable that agonists that target more than a single PPAR might be suitable for treating or preventing cancer. Bezafibrate is a pan-PPAR agonist but some of its effects are mediated by PPARα 7 . A number of studies suggest that bezafibrate can inhibit colon tumorigenesis in both rodent [199] [200] [201] and human cancer models 202 . Support for the idea that this is mediated by PPARα comes from data showing that a specific PPARα agonist, methylclofenopate, also inhibits intestinal tumorigenesis 203 . The molecular mechanisms underlying the effects of bezafibrate and methylclofenopate on colon tumorigenesis remain elusive. Bezafibrate can also cause growth arrest and can induce terminal differentiation and apoptosis in Burkitt's lymphoma cells, and these effects are enhanced by cotreatment with medroxyprogesterone acetate (MPA) 204 . These changes are partly mediated by an increase in the production of 15d-PGJ2, which is a natural ligand of PPARγ 204 . Moreover, bezafibrate induces similar changes in growth, differentiation and apoptosis in B cell chronic lymphocytic leukaemia cells, and co-treatment with MPA enhances these effects through a similar mechanism that is mediated by increased production of 15d-PGJ2 and apparent activation of PPARγ 205 . These observations suggest that the pan-PPAR agonist bezafibrate might target myeloid cancers through a mechanism that increases PPARγ activity. As bezafibrate activates PPARα, it remains a possibility that PPARα is required for these effects, but this has not yet been determined (FIG. 5) . The recent clinical trial demonstrating that bezafibrate is chemopreventive for colon cancer in humans 202 supports the hypothesis that the development of pan-PPAR agonists with relatively lower affinity for the PPARs (that is, μM versus nM) could be suitable for future chemopreventive approaches. Indeed, studies suggest that high-affinity dual-PPAR agonists can cause tumours, including bladder cancer, liposarcomas and haemangiosarcomas, in long-term bioassays 206 , indicating that the use of low-affinity agents might be a more suitable approach. The identification of new dual-or pan-PPAR agonists could be feasible because PPAR ligands can lead to unique alterations in gene expression partly based on differential recruitment of co-activators 191 . This could lead to the characterization of chemicals that do not exhibit the negative side effects that are associated with PPAR ligands, including pro-carcinogenic effects in preclinical models 206, 207 . In fact, dual-and pan-PPAR agonists might also help offset the side effects observed with more selective PPAR agonists. For example, weight gain or bone fractures observed in response to administration of PPARγ agonists [187] [188] [189] [190] 206 might be offset by agonist activity for PPARα or PPARβ/δ, which can increase lipid catabolism and can stimulate osteoblast activity in bone 208 . As there is also good evidence that combining PPAR activation with other chemopreventive or chemotherapeutic agents can significantly increase anticancer activities 92, [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] , it remains possible that dual-or pan-PPAR agonists could lead to even greater improvements in efficacy.
Conclusions
Agonists for all three PPARs induce many physiological changes, including increased oxidation of fatty acids, which contributes to reducing serum lipids and decreasing body weight; improved insulin resistance; and inhibition of inflammatory signalling. As metabolic syndrome, obesity, dyslipidemias, glucose intolerance and chronic inflammation are associated with increased cancer risk 106, 162, 163 , there are good reasons to suggest that PPAR agonists should be potential candidates for treating and preventing cancer. PPARα remains a viable target for the treatment and prevention of cancer because of evidence indicating that humans are refractory to the hepatocarcinogenic effects of PPARα agonists, and because PPARα agonists can exhibit anti-inflammatory and anti-carcinogenic effects. PPARγ also remains a potential target for the treatment and prevention of cancer, in particular for PPARγ agonists with good safety profiles. By contrast, whether PPARβ/δ is suitable for targeting for the treatment and prevention of cancer is uncertain because of numerous conflicting studies. It is interesting to note that there is an overlap in target genes that are regulated by each PPAR, but the physiological effects induced by selective PPAR agonists are unique owing to the complexity of the PPAR-dependent and the PPARindependent effects that each agonist induces. This also illustrates the complexity of PPAR regulation and the effects resulting from receptor activation, and why considerable research and drug discovery efforts are necessary to fully delineate the potential of targeting PPARs for the treatment and prevention of cancer.
